Microbioz India November 2018 Issue

39

33

33

31

35

29 Cover Story

14

The cover story of the month titled: Digital Marketing- Bringing Revolution in the Pharmaceutical Sectorcovered by our editorial team, the story features The Pharmaceutical companies operate in a regulated environment which poses constraints in the nature of promotional and marketing activities they can pursue. It has been observed that mostly the pharmaceutical promotional initiatives consist of below – the-Line (BTL) activities with an objective to engage their customer segment with the healthcare professionals with a positive brand experience.

Featured article

29

Added to this, the current edition has a special featured article titled10 year Zero Replacement Gaskets! Guarantee Long Life Gasket/ Sealing Solutions!

With advancements in Seal Engineering and access to best technology platforms from across the globe; Unispares™ now have developed break through sealing solutions for complex Industrial applications by Arihant Jain

Product Launches

31

The edition also covers recent Healthcare news articles and product launches collected from worldwide sources to update the readers with the current trends in the industry

Sun pharma reports posts Q2 loss at Rs 219 crore on one-time charge

19

Bengaluru: Sun Pharmaceutical Industries was sent to an unexpected second-quarter loss by a one-off charge for an antitrust litigation settlement. India’s largest drugmaker by market capitalisation made a provision of Rs.1,214 crore ($167 million) for estimated settlements with remaining plaintiffs in US antitrust litigation related to its sleep disorder drug Modafinil, leaving it with a Rs219 crore loss in the three months to September . 30, the company said.

Cosmo to give Bausch Health a run for its money with FDA nod for Xifaxan rival

21

Cosmo may not ring a bell for some industry watchers, but Aemcolo could seriously challenge Xifaxan and put a dent in Bausch’s recovery plan, one analyst said.As Wells Fargo's David Maris sees it, the Friday nod “is the first step toward an eventual significant slowdown and potentially a decline in Xifaxan revenues,” he wrote in a Monday note to investors.

Microbioz India, November 2018 10

ear friends and readers, I hope you would have enjoyed reading our previous issue. Once again, I am delighted to bring for you the new edition of your favourite magazine Microbioz India. It is a “Laboratory Edition” supported by the cover story titled Digital Marketing- Bringing Revolution in the Pharmaceutical Sector by covered by our editorial team.

The Pharmaceutical companies operate in a regulated environment which poses constraints in the nature of promotional and marketing activities they can pursue. It has been observed that mostly the pharmaceutical promotional initiatives consist of below – the-Line (BTL) activities with an objective to engage their customer segment with the healthcare professionals with a positive brand experience.

The current edition has also brought for you a featured article on “10 year - Zero Replacement Gaskets! Guarantee Long Life Gasket/ Sealing Solutions! ” from Unispares™ by Arihant Jain CEO-Director, (IIT-Madras) National Rubber Industries, includes with advancements in Seal Engineering and access to best technology platforms from across the globe; Unispares™ now have developed break through sealing solutions for complex Industrial applications.

We have the latest market research news and insightful product launches inside collected from worldwide sources to keep you updated with what is going on in the industry.

Dear friends and readers, I hope you find some value in the magazine. Also, I would like to thanks you for being together in the beautiful journey so far. We will wait for your valuable feedback and suggestions as they help us come with better content each time. For any further value addition, please write to us at editor@microbiozindia.com.

Cover Story

Digital Marketing- Bringing Revolution in the Pharmaceutical Sector he Pharmaceutical companies operate in a regulated environment which poses constraints in the nature of promotional and marketing activities they can pursue.

It has been observed that mostly the pharmaceutical promotional initiatives consist of below – the-Line (BTL) activities with an objective to engage their customer segment with the healthcare professionals with a positive brand experience. Across the globe many of the pharmaceutical companies are experimenting with the digital medium to capture the attention of their targeting audiences by create unique brand engagements and clock brand equity with health care professionals.

According to post published on MOPharma, the digital wave is sweeping across the $17 billion Indian pharmaceutical industry and majority of the companies

T

are dumping old ways of marketing over newer technology. These new technologies ranges from scientific detailing of the doctors by using newer algorithms for better insights among the issues such as patient compliance. The trend matches a similar switch in China over the last few years.

Mobile apps and social media play a bigger role in this growth, according to a study report on global digital marketing trends it was found that this will help India in catching up with tech-savvy emerging markets peers like China, where nearly half the companies are expected to allocate more than a fifth of their marketing budget to digital marketing by 2018.

Microbioz India, November 2018 14

Cover Story Digital Marketing should now be part of your overall marketing strategy, no matter which industry you are in.

As you might have guessed from above, it is true for Pharma Industry as well. Digital marketing in pharma industry has already picked up and starting to transform the Pharma and Healthcare industry in the ways it has already transformed retail, media, banking, airline, telecom and education industries.

Pharma industry is experiencing revolution with programs like Digital India & Make in India.

Social media platforms and health apps are expected to make a huge impact. According to reports, marketing expenditures on digital technologies is expected to touch Rs. 220 Crores by 2018.

Pharma companies and its executives have realized the potential and the disruption it can bring-in the pharma sector and have already started making use of and experimenting with the wide range of armaments available in Digital Marketing.

The pharma companies are dumping old ways of marketing using newer technology. The new technology ranges from scientific recording to online prescriptions to provide efficient solutions. Directors in the Pharmaceutical industry see the significance of Digital Health in the future and need to ensure successful implementation of similar strategies.

Historically, pharma companies have controlled both the generation and dissemination of information about their products. Digital technologies have weakened that control, opening an array of new and independent information channels. There are online communities for sharing and discussing patients' experiences, apps and sensors to monitor the impact of therapy on a patient's daily life, and advanced data aggregation and analysis to link disparate, complex data sets and generate new insights into drug safety and efficacy. In response, pharma companies will have to build the capabilities to anticipate or react rapidly to these new sources of evidence, and remain the main source of authority on the performance of their products.

Advanced analytics, sensors, and the automation of complex decisions are capable of delivering a step change in the efficiency, speed, quality, and responsiveness of business processes in all industries. The pharmaceutical industry is no exception. To thrive in a digital world, pharma companies will need to deploy next-generation technologies to streamline their business processes. They need to achieve near real-time transparency of their clinicaltrials portfolio in R&D, for example, and frictionless sales and operations planning in the supply chain, as well as meet new expectations in efficiency and agility from customers, employees, patients, and suppliers.

According to blog report published in http://www.pharmexec.com, If this wasn’t before, then there was clear evidence that digital media and marketing is not perfect. But perfect or not, it continues to deliver unprecedented reach,

Nevertheless, pharma industry has to go many miles to make full use of digital technology. More than 50% of companies do not have plans in place or are currently in the process of evaluating and adopting Digital Health plans. Digital Health solutions are still motivated by the marketing department as most companies are using Digital Health for their marketing and sales business, while only a few considered it as a great significance for the entire organization. New techniques and partnerships are essential for successful layout, implementation, and management of Digital Health solutions. Digital health solutions are seen as a generator of new business. Pharma companies need to find ways to not only price their Digital Health solutions but also need to make confusion on who’ll pay them.

Note: The above story is for information purposes to create awareness in pharma digital marketing.

References:

https://www.dr-hempel-network.com/growth-ofdigital-health-market/pharmaceutical-companies-anddigital-health-india/ file:///C:/Users/ROMI/Downloads/article_wjpps_14 59426072.pdf http://mopharma.com/blogs/pharma-digitalmarketing-12.html https://www.digitalvidya.com/blog/digital-marketingin-pharma-industry/

growing engagement, and real potential for building long-term brand awareness. eMarketer’s projections show that healthcare and pharma spend the least on digital advertising among the 10 industries measured. Retail is the biggest and will outspend healthcare and pharma by $20 billion in 2020 if eMarketer’s projections hold up.

Microbioz India, November 2018

16

Market Research Indian pharmaceutical companies have been hit

by US regulatory bans and warnings over quality control violations at production plants, which have weighed on profitability.

Pricing pressure has also weighed on performance in the United States, though sales have begun to show improvement.

This story has been published from a wire agency feed without modifications to the text. Only the headline has been changed.

Sun pharma reports posts Q2 loss at Rs 219 crore on one-time charge

Bengaluru: Sun Pharmaceutical Industries was sent to an unexpected second-quarter loss by a one-off charge for an antitrust litigation settlement.

India’s largest drugmaker by market capitalisation made a provision of Rs.1,214 crore ($167 million) for estimated settlements with remaining plaintiffs in US antitrust litigation related to its sleep disorder drug Modafinil, leaving it with a Rs219 crore loss in the three months to September .30, the company said.

Adjusted net profit for the quarter was Rs 996 crore, against a Rs912 crore profit in the same period last year and analyst expectations for a profit of Rs1,035 crore, according to I/B/E/S data from Refinitiv.

Total revenue from operations was Rs6,938 crore, up 4.3%, while US sales, which account for more than a third of total sales, rose 11% to $342 million.

Mylan West Virginia plant tagged with warning letter by FDA The other shoe has finally dropped on Mylan’s troubled manufacturing plant in West Virginia.

The drugmaker acknowledged Tuesday that the FDA this month issued a warning letter for the problems at the massive site.

The acknowledgement came after FDA Commissioner Scott Gottlieb publicized the warning letter in a Tweet.

The agency posted the letter Wednesday.

Mylan in a statement said the Nov. 9 warning letter was tied to the problems the FDA had already laid out in a 32-page Form 483 in April. It pointed out that it is in

Microbioz India, November 2018

19

Market Research the midst of dealing with those issues with a “comprehensive restructuring and remediation plan" at the Morgantown facility.”

"These activities are already reflected in our 2018 outlook, and the issues raised in the Warning Letter are being addressed within the context of this plan," the statement said. "We have been in regular communication with FDA and will continue to work to ensure that the Agency is satisfied with the steps we have taken to resolve all the points raised in the Warning Letter."

RBC Capital Markets analyst Randall Stanicky agreed that the additional FDA action should not make much difference to Mylan's investors since the problems have already been baked into investors' expectations. The stock didn't move much when the market opened Wednesday.

The warning letter generally follows the agency's 13observation Form 483 which chastised senior management for poor oversight by the plant’s quality control department, major lapses in equipment cleaning, ineffective laboratory controls, problems with sampling and more.

But it goes further by pointing out that many of the issues are repeats of problems mentioned in a 2015 warning letter for three other plants. "These repeated failures at multiple sites demonstrate that Mylan’s management oversight and control over the manufacture of drugs is inadequate."

The company in the second quarter began a remediation effort that included simplifying the plant by eliminating production of some low-margin drugs, moving production of other drugs to alternate facilities and laying off 500 workers. The fixes, which Mylan has acknowledge will stretch at least into next year, have not come cheap. Through September, Mylan had spent $184.2 million on the fix-up and restructuring charges, with nearly $100 million of that coming in the third quarter.

Mylan President Rajiv Malik in the third-quarter analyst call indicated the remediation and downsizing will not be too hard on the company’s sales going forward. He pointed out that only one of Mylan’s top 10 drugs and only eight of its top 50 gross margin-generating products for North America are manufactured in Morgantown.

The story is originally published in fiercepharma, shared here for information purposes.

Cosmo to give Bausch Health a run for its money with FDA nod for Xifaxan rival Bausch Health has yet to fully recover from its tainted past, and a new threat in the form of a rival to its topseller Xifaxan could pile more pressure on the drugmaker.

The FDA approved Cosmo Pharmaceuticals’ antibiotic Aemcolo—which belongs to the well-established rifamycin drug class—to treat patients with travelers’ diarrhea caused by noninvasive strains of E. coli. The company’s subsidiary, Aries Pharmaceuticals, is now eyeing a launch in the first quarter of 2019.

Cosmo may not ring a bell for some industry watchers, but Aemcolo could seriously challenge Xifaxan and put a dent in Bausch’s recovery plan, one analyst said.

As Wells Fargo's David Maris sees it, the Friday nod “is the first step toward an eventual significant slowdown and potentially a decline in Xifaxan revenues,” he wrote in a Monday note to investors.

Xifaxan is without doubt one of the most important products for Bausch. For the third quarter, its sales grew 11% year-over-year and constituted 15% of the company’s third-quarter sales total of $2.1 billion, according to the company’s quarterly securities filing from earlier in November.

Bausch has previously played down the threat of a competitor entrant, having told Maris’ team that the majority of Xifaxan sales actually came from irritable bowel syndrome, while traveler’s diarrhea only accounted for less than 10% of sales.

“We disagree,” wrote Maris.

Aemcolo will likely come at a discount to Xifaxan, which could give rise to off-label use in IBS-D and hurt Xifaxan’s growth, Maris said. Besides, Cosmo is already

Microbioz India, November 2018 21

Market Research in phase 2 studies for IBS-D, a program that Maris said has been derisked given the approval on Friday.

To make the situation more perilous for Bausch, Aemcolo could potentially land as a twice-daily regimen in IBS-D, versus Xifaxan’s more frequent three-timesper-day schedule.

The Cosmo drug’s approval now in travelers’ diarrhea was based on two phase 3 studies where it was given at twice daily for three days.

Novartis scores FDA nod for new Promacta use—and hops in the fast lane for another

Should Aemcolo succeed, it would have a clear convenience advantage over the Bausch drug. And even if it eventually has to go with the same dosing as Xifaxan’s, “it is competition for Xifaxan it has not had before,” Maris noted.

As the phase 2 readouts are expected in 2019, Maris is modeling Aemcolo’s launch in IBS-D in 2021 or 2022.

Bausch Health has been trying to repair its image after its notorious relationship with now defunct specialty pharmacy Philidor mired it in scandal, and it’s also counting on newer drugs to help pay off debt incurred during its pre-Philidor M&A frenzy. But plaque psoriasis therapy Duobrii, one of the “Significant Seven” drugs the company has dubbed as key growth drivers, was recently rejected by the FDA. Though the company immediately resubmitted, and a decision is now expected for February 2019, Maris has estimated the drug will never even reach $100 million in sales, as it’s a combination of two generic drugs.

On the flip side, the Canadian company recently picked up an FDA nod for another “Significant Seven” drug, Bryhali, in plaque psoriasis. And it has exclusively signed on to co-promote US WorldMed’s opioid withdrawal drug Lucemyra and Dova Pharmaceuticals’ thrombocytopenia treatment Doptelet in the U.S. The story is originally published in fiercepharma, shared here for information purposes.

When Novartis paid $16 billion to acquire GlaxoSmithKline’s cancer portfolio back in 2015, it picked up a few drugs that didn’t seem to have quite so clear growth prospects, including Promacta to treat anemia and platelet diseases. But Novartis kept toiling to expand the label for Promacta, which at the time was bringing in about $117 million a year—and there’s new evidence that those efforts are paying off for the company.

Novartis said Friday that the FDA approved Promacta for the first-line treatment of severe aplastic anemia (SAA) in adults and children two years and older, in combination with immunosuppression. It also granted a breakthrough designation to the drug for use in treating acute radiation syndrome, more commonly called radiation sickness.

Sales of Promacta grew 37% year over year in the first nine months of this year, to $844 million. A spokesperson for Novartis didn't provide specifics about how the size of the patient population could grow with the latest label expansion. Severe aplastic anemia is rare: two out of every 1 million people in Europe and North America are diagnosed with the disease each year, he said.

Microbioz India, November 2018

23

Market Research As for radiation sickness, that market is effectively nonexistent, because Promacta would only be used to protect people in the event of a nuclear accident or attack.

"We hope that it will never have to be used," the spokesman admitted. "However, we will be prepared if called upon."

Although Promacta doesn’t address a huge market by any stretch, the SAA label expansion will allow Novartis to reach patients earlier in the treatment process, rather than waiting for them to fail immunosuppressive treatment. The FDA based its approval on an analysis of research performed by Novartis, which showed that 44% of aplastic anemia patients who had not been treated before had a complete response to Promacta combined with immunosuppression at six months. That bested the observed response rate to immunosuppressive drugs alone by 27%.

“Patients with SAA sometimes do not respond to the current treatment standard,” Phillip Scheinberg, M.D., head of the division of hematology at Hospital A Beneficência Portuguesa de São Paulo in Brazil, said in a statement, adding that the ability to add Promacta to immunosuppression upon diagnosis would be valuable to physicians and patients. Scheinberg previously served in the hematology branch of the National Institutes of Health’s National Heart, Lung and Blood Institute (NHLBI), which sponsored Novartis’ research.

Novartis has also filed for approval in Europe for Promacta in first-line SAA. The company said it expects a decision next year.

The news came just a few weeks after Novartis suffered a disappointment in another effort to expand the label of a product that addresses a small patient population.

The company had sought approval for its cardiovascular drug Ilaris in the treatment of some patients who had suffered heart attacks. But the agency rejected the label expansion, citing a need for additional clinical trial data on the patients who responded to the drug.

The prospects for a label expansion on Ilaris, which is currently approved to treat rare inflammatory diseases, didn’t seem all that promising last August, when Novartis released clinical trial data showing that the drug produced a 15% reduction in risk for major cardiovascular events and a 10% lower risk of cardiovascular death. Analysts were underwhelmed— and concerned about a risk of infections that seemed higher in the Ilaris group than it was in people taking a placebo.

Disappointments aside, Novartis’ executives remain optimistic about the company’s overall growth prospects. During the company’s third-quarter earnings release in mid-October, they raised their revenue estimate for the year, telling analysts to expect sales to grow by a mid-single digit percentage, rather than the low- to mid-single digit rate they had previously forecast.

The story is originally published in fiercepharma, shared here for information purposes.

Market Research

Lactic Acid Quality — Analyze Nitrogen, Sulfur, and Chlorine Regardless of the Matrix Lactic acid is one of the world’s most popular biochemical, especially in the food and cosmetics industries. It is used as a raw material for the production of sustainable biopolymers and is a preservative, tasteenhancer, or PH-regulating component in many foods.

High-quality lactic acid is crucial for subsequent production processes as well as the quality of the finished product. So, it is important to consistently avoid containments.

There are various solutions to analyze lactic acid for chlorine, sulfur, and nitrogen, but only one for optimal analysis: the multi EA 5000 from Analytik Jena. This elemental analyzer is both easy to use and has shown the most reliable performance in analyzing organic raw materials. The multi EA 5000’s innovative flame sensor automatically detects the ideal combustion temperature for each matrix type. In combination with powerful detection systems, this guarantees the best analysis results.

Time-consuming sample preparation is completely eliminated with the multi EA 5000, regardless of the combustion behavior of the sample matrix.

Companies and contract laboratories in the food and cosmetics industries need analytical tools that integrate

seamlessly into existing process chains, deliver reliable results, and do not cause any losses in efficiency. The multi EA 5000 does all of this and also brings high user comfort to the lab.

Further information about lactic acid analysis with the multi EA 5000 is available at www.analytikjena.de/multiEA/AppNotes.

Lactic Acid Quality – Analyze Nitrogen, Sulfur, and Chlorine Regardless of the Matrix. There are various solutions to analyze lactic acid for chlorine, sulfur, and nitrogen, but only one for optimal analysis: the multi EA 5000 from Analytik Jena.

Accredited with Drug master File 032687 by US FDA Dept for Mfg of Silicone/ FKM/ EPDM Moulded& Extruded Products A N A T I O N A L G R O U P C O M P A N Y

|

S i n c e

1 9 7 8

#10 year - Zero Replacement Gaskets!

Guarantee Long Life Gasket/ Sealing Solutions!

With advancements in Seal Engineering and access to best technology platforms from across the globe; Unispares™now have developed break through sealing solutions for complex Industrial applications.

Unispares™Polymer Industries Pvt. Ltd. possesses almost 4 decades of In-House Manufacturing expertise and Research Engineering experience from countries prestigious institutions like IIT Madras. We also have tied up with Global Sealing Solutions manufacturers like IDT (Germany) and KWO (Germany), by bringing in

latest technology at Indian door steps.

This unique combination of Robust Manufacturing Base, R&D and German technology is the major factor behind solving complex industrial applications, especially in Pharmaceutical and Biotechnology sectors.

Pharmaceutical, Biotechnology and F&B have been pioneer fields when it comes to technological advancements and upgradation to best manufacturing practices. These sectors have been under a constant need to meet growing global compliances and standards.

Unispares™have been a reliable partner to its customers in supplying supreme Quality products, Engineering & Audit Consultancy, Product Trainings and Turnkey Project Executions.

We have been fortunate to been associated with our key clientele during major FDA Audits and compliances by providing our services. With a highly qualified team, We have numerous success stories in supporting clients in going through critical Audits and observations.

Unispares™Polymer Industries Pvt. Ltd. believes very strongly in developing consumables which lasts long.

We always try to work on

"Longer Gasket Life, Lesser Replacement Frequency".

For some of our products, we assure 10year-Zero Replacement guarantee. Gasket once installed need not be changed for 10 years or more* (subjected to application, design & other parameters). These products have proven to be revolutionary in terms of arresting leakages, increasing operational efficiencies and most importantly lower production stoppages/ Equipmentdowntime.

Gasket selection requires a detailed understanding about

exact application, operating parameters& conditions and media. Compatibility of product under existing application is what forms the basis of selecting the best suited Sealing solution.

Few of our flagship products include: Unispares™PERG Series (Ptfe Encapsulated Rubber Gasket) Unispares™ FERG Series (FEP Encapsulated Rubber Gasket) ePTFE& advanced PTFE product grades Unispares™FFKM Range Unispares™OEM division solutions Unispares™Hose Technology and many more.

Feel free to contact our area representative.

Thanks, Arihant Jain | +91-9490934575 CEO-Director | PGDM IIT Madras Unispares Polymer Industries Pvt. Ltd.

Microbioz India, November 2018

29

Product Launch

Miniature 2-Way Inert Solenoid Valve for Critical Fluid Control Innovation in miniature continues to be the mission for THE LEE COMPANY proven by their ability to develop innovative miniature precision fluid control components.

A good example of this is their new LFV Series 8000 2way inert solenoid valve which is ideal for critical flow applications in clinical chemistry, flow cytometry and haematology machines.

These 2-way chemically inert isolation style valves represent the next generation of the classic 2-way, normally closed (NC) inert LFV valves providing an on/off function in a critical fluidic circuit ensuring zero dead volume and extremely low internal volume. They incorporate a diaphragm seal that isolates the fluid from the inner components to provide a consistently reliable switching performance. They are also rated for bidirectional flow and feature a contoured path design which allows for complete flushing capability.

The valves small size ensures a more compact instrument footprint and means less fluid is needed enabling closer valve spacing. Other key benefits include; long-life operation which contributes toward reduced maintenance and lower installed cost, low power consumption ensuring less heat generated and a smaller power supply. They are chemically inert, flushable, and critical fluids are only in contact with the port head and diaphragm with no metallic contact.

They are flow rated at 1250 Lohms maximum and pressure rated at vacuum to 30 psi and are available with push on ports for soft tubing or two manifold mount styles, which now utilise O-rings instead of gaskets made from the same material as the diaphragm.

LFV valves are generally used in medical and scientific applications including in-vitro diagnostics, human genomics, biotechnology, environmental analysers and other critical OEM devices. Each valve is 100% functionally tested for performance and use materials that ensure a consistent and long-life performance.

For more information:https://www.theleeco.com/

Next Generation FluidScanÂŽ Portable Oil Analyzer from Spectro Scientific Features Upgraded Electronics, Software, Memory and Ergonomics

Spectro Scientific, one of the world’s largest suppliers of oil, fuel, and processed-water analysis instrumentation and software, has released a new generation of its fieldproven FluidScanŽ mid-infrared spectrometer handheld oil analyzer.

Patented FluidScan technology collects light transmitted through drop of a fluid sample and registers the infrared absorption spectrum. The analyzer compares spectrum to a built-in fluid reference library provid, on-site analysis of in-service lubricants. Analysis takes less than one minute, users no special training and the process requires no solvents or complicated cleanup.

The new generation FluidScan analyzers have upgraded digital electronics and faster embedded processors with new software and calculation algorithms that speed the analysis process. It hosts more data and algorithm storage with much larger memory.

Microbioz India, November 2018 31

Product Launch The new oil library includes almost 800 oils and greases of a wide range of chemistry and brands. Thegrease library is significantly expanded and a new water index parameter helps users track dissolved water trends in used grease.

of FluidScan analyzers and also illustrates the continual improvement of Spectro products overall, as our company constantly works to provide our customers with the most advanced, precise and convenient fluid analysis tools possible.”

For more information: https://www.spectrosci.com/

Mass Spectrometry Software Accelerates Small-Molecule Characterization

Thermo Scientific Mass Frontier 8.0 software with Thermo Scientific Orbitrap ID-X Tribrid Mass Spectrometer streamlines small-molecule unknown compound identification and structural elucidation Pharmaceutical scientists are now able to overcome challenges associated with the identification and characterization of small molecules and their fragments with Thermo Scientific Mass Frontier 8.0 software,

New software algorithms include a fluid integrity parameter that permits users to determine if a substance with a different chemistry is mixed with the lubricant, a common problem in oil top-off process. In addition, a new biodiesel detection algorithm measures the percentage of biodiesel fluid in engine oil.

When combined with the Spectro Scientific FDM 6000 series fuel dilution meters, a more accurate measurement of total biodiesel and diesel dilution percentage can be obtained. Fuel dilution is one of the biggest problems identified in engine oil analysis.

A new ability to make corrections to stored factory fluid data eliminates the need to create new user fluid entries to correlate FluidScan results with those from commercial laboratories.

Ergonomic improvements include a 50 percent larger and brighter LCD screen. A new LED light in the sampling head enables users to quickly check for air bubbles in an oil sample, supporting improvedmeasurement quality.

The new release of FluidScan analyzers includes two models. FluidScan 1000 is designed as a standalone unit for fleet operations or oil analysis labs, supported

by Spectro’s Fluid Manager software. FluidScan 1100 is engineered to operate on a standalone basis or as part of a Spectro MiniLab configuration. Fluid Manager software and the newly introduced TruVu 360™ Device Console (TDC) software support it.

Spectro Scientific president and CEO Brian Mitchell said, “This new release represents theongoing evolution

which quickly translates complex data into actionable, sharable knowledge.

Brought together by Thermo Fisher Scientific’s continuing 20-year collaboration with HighChem, Mass Frontier 8.0 software enables analysts to rapidly deconvolute and search information-rich, MSn mass spectrometric data produced during the identification and structural characterization of small-molecule unknown compounds and their fragments. Thermo Fisher showcased its latest chromatography and mass spectrometry solutions at the 12th Annual Meeting of the American Association of Pharmaceutical Scientists (AAPS 2018).

“Small-molecule unknown compound identification and analysis using mass spectrometry generates large quantities of complex data, which is labor intensive and time-consuming to process and confidently turn into knowledge,” said Iain Mylchreest, vice president, research and development, analytical instruments,

Microbioz India, November 2018 33

Product Launch Thermo Fisher Scientific. “Through its powerful algorithms and fully-curated knowledge databases of spectral and fragmentation data that covers 95% of all published fragmentation pathways, Mass Frontier 8.0 software accelerates small-molecule characterization.”

“We have been using the Mass Frontier software for over 10 years in the UC Davis Fiehn Lab and think every mass spectrometrist should have a copy of Mass Frontier software,” said Dr. Tobias Kind, Genome Center, Metabolomics, University of California, Davis.

“The functionality of mzCloud integration, as well as the look and design, is well-organized and intuitive.”

The Mass Frontier 8.0 software enables scientists to go from complex data to actionable, sharable insights by: Making unknowns known through searching deconvoluted components against mzCloud, the world’s most comprehensive mass-spectral database Providing confidence in data through access to a fragmentation library of more than 52,000 schemes, all of which are curated from peer-reviewed scientific papers Building pathways to knowledge with access to the Metabolika biological pathway database, providing 370 curated biochemical pathways with annotated reactions and corresponding metadata for various organisms Constructing, storing and managing spectral libraries using the Data Manager software, providing the ability to share this knowledge across a network or organization In combination with the Thermo Scientific Orbitrap ID-X Tribrid Mass Spectrometer supporting the Thermo Scientific AquireX intelligent MSn data acquisition strategy, Mass Frontier 8.0 software can be used to capture more low-abundance analytes through streamlined data analysis and mass spectral prediction tools. This eliminates the labor-intensive and timeconsuming steps analysts face when identifying smallmolecules and their respective fragments using traditional solutions, providing greater insights, understanding and confidence when turning data into actionable knowledge.

For more information: https://www.thermofisher.com/in/en/home.html

Bio-Logic & Hinds launch EKKO® the world’s first high throughput microplate reader for circular dichroism Breakthrough technology cuts screening time by 10 times compared to circular dichroism (CD) devices with auto samplers and is at least 100 times faster than standard HPLC processes.

Bio-Logic (France) and Hinds Instruments (United States) are pleased to announce the launch of the EKKO®, the world’s first high throughput CD microplate reader. EKKO® demonstrates significant potential for the pharmaceutical industry and any organization working in the field of asymmetric synthesis, catalysis and organic/medicinal chemistry.

This compact device can screen a 96 well plate in under two minutes, as opposed to several hours compared to a traditional CD spectrometer linked to an auto sampler.

This exponential increase in speed could dramatically improve the efficiency of chiral R&D campaigns.

Furthermore, the device is not just faster, but more cost-efficient. It uses 10 times less nitrogen than a standard spectropolarimeter with auto sampler and 4 times fewer samples at a comparable light path.

As well as being significantly faster than supercritical fluid chromatography (SFC) and high performance liquid chromatography (HPLC) protocols, the device is able to identify enantiomeric excess (ee) rates as well as yield resulting in data that can prove highly beneficial to the screening process. It is also more environmentallyfriendly as it requires no solvents.

Microbioz India, November 2018 35

Product Launch According to Hinds’ senior scientist Bob Wang: “This CD reader eliminates the time-consuming process of transferring the contents of each well of the micro-well plate into a cuvette, and cleaning between each measurement, as is necessary when using conventional CD spectrometers.

Furthermore, by avoiding chromatography completely, EKKO® is well suited to identifying ‘hits’ quickly using high throughput screening.”

Story source: Bio-Logic Science Instruments

Tomocube Launches 23-Strong Distributor Network Global support for Holotomography Microscopy as company prepares for introduction of second microscope model

A comprehensive network of specialist imaging companies has been unveiled to support the sales and maintenance of Tomocube’s holotomography microscopes around the world. Covering North America, Europe and Asia, the 23-strong group is being launched as Tomocube prepares to introduce its second microscope model in less than three months.

According to Aubrey Lambert, Tomocube’s Chief Marketing Officer, “Major life science research and diagnostic facilities around the world have welcomed the new Tomocube HT-1 holotomography microscope for the way it overcomes many of the limitations facing cellular analysis. To make sure we support these scientists, we are delighted to have brought together into our distributor group some of the world’s finest microscopy and imaging companies. Each has invested significantly in demonstration facilities that researchers and scientists are invited to visit. What’s more, other countries are set to join the network over the next

months and a full list may be found at www.tomocube.com.”

The launch of the new network comes as Tomocube readies a sister microscope to the just-launched HT1.

Sharing the HT-1’s patented light shaping digital micromirror device that generates the unique 3D tomograms, the new instrument will incorporate complementary imaging capabilities to help researchers and clinicians understand, diagnose and treat human diseases.

Story source: Tomocube

ZEISS and arivis AG Intensify Strategic Partnership Joint further development of 3D visualizations of multidimensional image data ZEISS and arivis have now expanded and deepened their cooperation, which began in 2014. The companies are pursuing the common goal of enabling new findings in life sciences and in materials research by improving the presentation and analysis of digital data.

Modern microscope systems with high-resolution optics record ever increasing amounts of data, which can only be displayed and analyzed with the help of advanced software. This requires powerful algorithms and applications that allow these very large, complex multidimensional data to be displayed without delay and evaluated automatically.

Within the framework of the partnership, arivis will continuously develop the 4D visualization solution already integrated into the ZEISS software.

Furthermore, ZEISS will offer high-end software products from arivis together with 3D microscopy systems to better address customer applications. Thus it is becoming possible for users of such systems to quantitatively evaluate multidimensional image data in highest quality and reliability.

Microbioz India, November 2018

37

Product Launch Furthermore, arivis and ZEISS have agreed to jointly advance new developments and to further optimize the interaction between hardware and software in a userfriendly manner. arivis will also contribute its expertise in the areas of virtual reality and web-sharing technologies and, together with ZEISS, continue to shape future developments for 3D applications in academic and industrial research as well as quality assurance.

ZEISS and arivis are also cooperating on the new cloudbased digital microscopy platform APEER, the first version of which was recently presented to the public. arivis is implementing the visualization of the platform.

APEER combines various microscopic applications, especially for the further processing of images such as 3D reconstructions, staining and segmentation, and serves as an exchange platform. This gives microscopy users more time for research Story source: zeiss

New Peltier Cooling Module Optimizes Conditions for Temperature Sensitive Assays BioTek has released a Peltier Cooling Module for the Cytation™ Cell Imaging Multi-Mode Readers.

The compact module keeps internal temperature rise to less than one degree over ambient, regardless of fluctuations from external and internal factors. The module helps maintain and optimize stability for more consistent data in assays run at ambient temperature.

The module also quickly reduces internal temperature after incubated assays for efficient transitions between multiple applications with different temperature requirements.

The Peltier Cooling Module, along with a number of enhanced modular features, may be added to the Cytation family at any time as research requirements evolve. Cytation offers automated digital imaging and patented Hybrid Technology™ optics, along with

powerful Gen5™ software. The highly flexible system suits a wide range of cell-based and biochemical assays.

BioTek Instruments, Inc., headquartered in Winooski, VT, USA, is a worldwide leader in the design, manufacture, and distribution of innovative life science instrumentation. Our comprehensive product line includes cell imaging systems, microplate readers, washers, dispensers, automated incubators, stackers and pipetting systems. These products enable life science research by providing high performance, cost-effective analysis and quantification of biomolecules, biomolecular interactions and cellular structure and function across diverse applications. BioTek espouses a "Think Possible" approach that sets the tone for fresh ideas, unsurpassed customer service and original innovations.

Story source: BioTek

New AutoScratch™ Wound Making Tool Enhances Reproducibility and Efficiency BioTek introduces the new AutoScratch™ Wound Making Tool to facilitate two dimensional (2D) collective cell migration and invasion applications.

With a simple pushbutton operation, the AutoScratch automatically creates consistent scratches of equivalent size and area in confluent cell monolayers grown in 24or 96-well microplate format. This eliminates variability found in manual scratch methods and increases the reproducibility necessary to analyze and normalize results across subsequent assays. The compact system easily fits into laminar flow hoods, while an integrated, multi-reservoir cleaning trough and pre-programmed method offer hands-free cleaning and decontamination of the interchangeable pin heads before and after use.

Microbioz India, November 2018 39

Product Launch AutoScratch is an ideal companion tool for cell biology workflows incorporating BioTek’s Cytation™ Cell Imaging Multi-Mode Readers and Lionheart™ Automated Cell Imagers. In addition to kinetically monitoring cell migration and invasion, the automated instruments include Gen5™ software to automatically calculate wound width, wound % confluence and maximum wound healing rate.

BioTek Instruments, Inc., headquartered in Winooski, VT, USA, is a worldwide leader in the design, manufacture, and distribution of innovative life science instrumentation. Our comprehensive product line includes cell imaging systems, microplate readers, washers, dispensers, automated incubators, stackers and pipetting systems. These products enable life science research by providing high performance, cost-effective analysis and quantification of biomolecules, biomolecular interactions and cellular structure and function across diverse applications. BioTek espouses a "Think Possible" approach that sets the tone for fresh ideas, unsurpassed customer service and original innovations.

Story source: Biotek

Kromasil silica-based packing materials were introduced in the market With more than 30 years in the market place, the Kromasil product line is made by the Separation Products group, or the Kromasil team, a group of people with skills in a wide range of areas. We are dedicated to our mission to develop outstanding packing materials for HPLC/SFC/SMB, to improve efficiency and decrease costs in your separation step.

When the first Kromasil silica-based packing materials were introduced in the market, they greatly improved the effectiveness of liquid chromatography. What made the new packing material so unique was the combination of high pore volume and surface area, together with a very high mechanical stability.

Today this combination of properties is still unmatched by other chromatography packings on the market.

Kromasil is a brand of Nouryon, formerly known as AkzoNobel Specialty Chemicals, a global company with about 10 000 employees in over 80 countries, a producer of essential chemistry with a shared commitment for business growth, safety, sustainability, and innovation, in strong partnership with customers.

For more information: shreetech.associates@gmail.com

Microbioz India, November 2018 41

Product Launch

NEW Hot Plates & Stirrers with 5 or 9 Positions

Torrey Pines Scientific, Inc. announces its new line of multi-position analog stirring hot plates and stirrers featuring 5 or 9 stirring positions.

The large 12” (305 mm) square ceramic heater tops have a temperature range to 450°C.

The 5-position stirring units can stir 5-800ml beakers, and the 9-position units can stir 9-500ml beakers of aqueous solutions from 100 to 1500 rpm. Each stirring position is individually controlled so different vessels can be stirred at different speeds at the same time on one plate surface.

The Models ST15 Stirrer and the HS15 Stirring Hot Plate can stir 5 vessels. The ST19 Stirrer and HS19 Stirring Hot Plate can stir 9 vessels. The units measure 19” (432 mm) deep by 12.5” (318 mm) wide by 5.25” (134 mm) tall.

They can support more than 50 pounds (22.6kg) on the plate surface. All controls are mounted well in forward of the heater surface to protect against accidental burns, and the units are designed to keep spills out of the chassis.

The units are available in 115 VAC/60Hz, 220 VAC/60Hz, and 230 VAC/50Hz. They have a main AC on/off switch and are fused for safety. They are supplied with user’s manual and detachable line cord for the country of use. All units are UL, CSA and CE or equivalent rated.

Story source:Torrey Pines Scientific

New Method for Characterising Liposome Formulated Drugs

Postnova Analytics has published an application study that describes a new method for quantification of liposome encapsulated drug using Centrifugal FieldFlow Fractionation (CF3).

Nanoparticles including liposomes are increasingly used for delivery of drug molecules. During formulation of a liposome around a drug particle, a relatively large amount of free drug may remain unencapsulated and therefore not available for drug delivery via the liposomal carrier. For formulation groups adopting this drug delivery methodology it is important to quantify the amount of free versus encapsulated drug in a product in order to accurately determine the delivered dose of drug to a patient.

In this study, Centrifugal Field-Flow Fractionation coupled with UV-Vis detection was shown to be able to separate and quantify the amount of free drug in a liposome-drug product. The separation data was verified using optical microscopy. The authors conclude that Centrifugal FieldFlow Fractionation shows great promise for separation and quantification of drug particles, as the field of nanomedicine and liposomal drug delivery grows.

The Postnova CF2000 Series system is based on the CF3 principle using a centrifugal field as driving force for the separation. Particles effected by this field are separated by dynamic diffusion based upon both their size and density.

This unique feature allows researchers to separate different particle materials having the same particle size. The separation can be further optimized by the use of different eluents and rotation speed programs. The CF2000 has shown great utility for the separation of complex nanoparticle samples in application areas including pharmaceuticals, environmental research, food, cosmetics and agrochemicals.

Story source:Postnova Analytics

Microbioz India, November 2018

43

RNI NUMBER: UPENG/2017/73675